Levetiracetam Tablet, Film Coated
Product Images NDC 50090-1333

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 50090-1333). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500901333)

Levetiracetam 500 mg film-coated tablets label showing product and manufacturer details. The label indicates the dosage form as oral tablets, with each coated tablet containing 500 mg of levetiracetam. The package contains 120 tablets and is labeled by A-S Medication Solutions, Libertyville, IL 60048. Storage instructions specify to keep between 68 and 77 degrees Fahrenheit.*

FDA Label Image

Label Image (Lbl500902875)

Levetiracetam 1000 mg film-coated tablets bottle label showing product name, strength, and dosage form. The label includes storage instructions to keep between 68 to 77 degrees Fahrenheit, package size of 30 tablets, and manufacturer A-S Medication Solutions, Libertyville, IL 60048. Additional details include NDC 50090-2875-0 and a QR code for dosage and packaging information.*

FDA Label Image

Levecamberlogo1

FDA Label Image

Levefig1

A bar graph depicting the percentage of patients showing results across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The vertical axis represents the percentage of patients, with values approximately 7.4% for Placebo, 37.1% for Levetiracetam 1000 mg/day, and 39.6% for Levetiracetam 3000 mg/day.*

FDA Label Image

Levefig2

A bar chart comparing the percentage of patients across three groups: Placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%). The x-axis labels the treatment groups with sample sizes, and the y-axis shows percentage of patients from 0% to 45%.*

FDA Label Image

Levefig3

Bar chart comparing the percentage of patients between placebo (N=104) and Levetiracetam 3000 mg/day groups, showing approximately 14.4% for placebo and 39.4% for Levetiracetam.*

FDA Label Image

Levefig4

A bar graph comparing the percentage of patients between a placebo group and a Levetiracetam treatment group. The vertical axis represents the percentage of patients, with the placebo group at approximately 19.6% and the Levetiracetam group at 44.6%. Patient counts for each group are also shown.*

FDA Label Image

Levefig5

A bar graph comparing the percentage rates of two groups: Placebo (N=64) at 45.2% and Levetiracetam (N=79) at 72.2%. The vertical axis represents percentage values, and the chart highlights a higher percentage for Levetiracetam compared to Placebo.*

FDA Label Image

Levefig6

A bar chart comparing the efficacy percentage of Levetiracetam versus placebo. The chart shows a higher efficacy percentage for Levetiracetam at 72.2%, compared to 45.2% for placebo, with subject counts of 79 and 64 respectively.*

FDA Label Image

Levestructure

Chemical structure of levetiracetam, showing the molecular arrangement of its atoms and bonds typical for this anticonvulsant compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.